Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gamma-glutamylcysteine in Repetitive Head Impact
NCT07050173Phase 1Recruiting
- Start
- May 2026
- Primary completion
- Nov 2027
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gamma-Glutamylcysteine in chronic traumatic encephalopathy (CTE). Primary endpoints: Changes in brain glutathione levels at 12 months, Changes in baseline blood glutathione levels at 12 months and 1 more. Started May 2026; status: recruiting.
02
Drugs
gamma-Glutamylcysteine
03
Conditions
chronic traumatic encephalopathy (CTE)
Beyond the preview
Go deeper on NCT07050173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07050173.